John Higuchi Buys 40,000 Shares of Lipocine (NASDAQ:LPCN) Stock

Lipocine Inc. (NASDAQ:LPCN) Director John Higuchi acquired 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 7th. The shares were bought at an average price of $2.03 per share, with a total value of $81,200.00. Following the transaction, the director owned 203,797 shares in the company, valued at $413,707.91. This represents a 24.42% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Lipocine Trading Up 6.5%

Shares of LPCN stock opened at $2.13 on Thursday. The firm has a 50-day moving average price of $7.78 and a 200 day moving average price of $5.74. Lipocine Inc. has a twelve month low of $1.81 and a twelve month high of $12.37. The company has a market capitalization of $15.55 million, a price-to-earnings ratio of -1.26 and a beta of 1.09.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.26. The company had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.12 million. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.

Hedge Funds Weigh In On Lipocine

Institutional investors have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new position in shares of Lipocine in the 3rd quarter valued at approximately $41,000. Jane Street Group LLC acquired a new position in shares of Lipocine in the 4th quarter valued at approximately $85,000. Renaissance Technologies LLC raised its position in shares of Lipocine by 3.6% in the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after purchasing an additional 1,300 shares in the last quarter. Boothbay Fund Management LLC bought a new stake in shares of Lipocine in the 4th quarter valued at approximately $441,000. Finally, Geode Capital Management LLC increased its holdings in shares of Lipocine by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after acquiring an additional 1,374 shares during the last quarter. 9.11% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Lipocine

Here are the key news stories impacting Lipocine this week:

• Positive Sentiment: Director John W. Higuchi purchased 40,000 shares at ~$2.03 (SEC-filed), increasing his stake materially — a strong signal of insider confidence that likely supported the stock’s intraday strength. Director John Higuchi Buys $81,200 in Lipocine Stock
• Positive Sentiment: CEO Mahesh Patel bought 25,000 shares at about $2.03, raising his holding nearly 18% — another direct insider purchase that may attract momentum buyers in a low-float, small-cap stock. Mahesh Patel Purchases 25,000 Shares
• Neutral Sentiment: HC Wainwright raised FY2026 and quarterly EPS estimates (narrowing projected losses) but maintained a “Neutral” rating — supportive to fundamentals but not a bullish analyst upgrade. HC Wainwright Neutral Rating and Estimates Update
• Neutral Sentiment: Lipocine’s recent quarter beat revenue and posted a smaller-than-expected EPS loss, which underpins the revised sell-side models but the company remains cash-consuming and loss-making. MarketBeat LPCN financial summary
• Negative Sentiment: Press coverage showed HC Wainwright language that could be interpreted as more cautious/downgrade-focused — any negative wording from a healthcare specialist can trigger short-term selling in thinly traded names. MSN: HC Wainwright Downgrades Coverage
• Negative Sentiment: Shareholder litigation inquiry announced by Johnson Fistel introduces legal risk and potential expense — a downside catalyst that can weigh on sentiment and valuation. Johnson Fistel Investigation Announcement

Wall Street Analyst Weigh In

Several research firms have recently weighed in on LPCN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lipocine in a research note on Friday, March 27th. HC Wainwright reaffirmed a “neutral” rating on shares of Lipocine in a research note on Monday. Finally, Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Lipocine currently has an average rating of “Hold” and a consensus target price of $15.00.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.